SRRK Stock: Scholar Rock Holding Corporation Stock Price, Analysis & Insights
Get live srrk stock price $37.41, comprehensive Scholar Rock Holding Corporation stock analysis, charts, news, and expert forecast. Real-time srrk stock data and investment insights.
Loading chart...
Company Overview
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- David L. Hallal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
Contact Information
- Website
- https://scholarrock.com
- Address
- 301 Binney Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.66) may provide portfolio stability
Business Model & Strategy
Scholar Rock Holding Corporation operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO David L. Hallal, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Scholar Rock Holding Corporation competes in the Biotechnology within the broader Healthcare. With 3.6 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Scholar Rock Holding Corporation provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Scholar Rock Holding Corporation should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Scholar Rock Holding Corporation shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Scholar Rock Holding Corporation
- ⚠Investors should consider how Scholar Rock Holding Corporation fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
3.60B
P/E Ratio
-12.81
Beta
0.66
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 3.60B market capitalization
- Trading Volume: 7.13M shares traded today
- Price Range: 52-week range of $22.71 - $46.98
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Scholar Rock Holding Corporation
Scholar Rock Holding Corporation (SRRK) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 3.60B, the company represents a significant player in its market. The stock is currently trading at $37.41 with a positivedaily change of 24.41%.
The company's 128 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -12.81, beta of 0.66, and 52-week price range from $22.71 to $46.98when evaluating investment opportunities.
Why Invest in Scholar Rock Holding Corporation?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under David L. Hallal
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.